Aarti DrugsNSE:AARTIDRUGS +0.56%73 ROA % is 7.84% as of Mar. 2026, which is 10% above its 10-year median of 7.14. GuruFocus rates NSE:AARTIDRUGS with a GF Score™ of 73/100 and a GF Value™ of ₹498.02 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Aarti Drugs ranks better than 73.43% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Aarti Drugs's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹2,208 Mil.
Aarti Drugs's average Total Assets over the quarter that ended in Mar. 2026 was ₹28,153 Mil. Therefore, Aarti Drugs's annualized ROA % for the quarter that ended in Mar. 2026 was 7.84%.
The historical rank and industry rank for Aarti Drugs's ROA % or its related term are showing as below:
NSE:AARTIDRUGS'
s ROA % Range Over the Past 10 Years
Min: 6.31 Med: 7.14 Max: 16.78
Current: 7.31
During the past 13 years, Aarti Drugs's highest ROA % was 16.78%. The lowest was 6.31%. And the median was 7.14%.
NSE:AARTIDRUGS's ROA % is ranked better than 73.43% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs NSE:AARTIDRUGS: 7.31
Aarti Drugs (NSE:AARTIDRUGS) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Aarti Drugs ROA % Related Terms
Aarti Drugs ROA % Historical Data
* Premium members only.
The historical data trend for Aarti Drugs's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Drugs ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's ROA % distribution charts can be found below:
* The bar in red indicates where Aarti Drugs's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Aarti Drugs (NSE:AARTIDRUGS) has a ROA % of 7.84% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Aarti Drugs and its competitors. This is 10% above median its historical median of 7.14. Over the past decade, Aarti Drugs' ROA % has ranged from 6.31 to 16.78. According to the industry distribution chart, Aarti Drugs ranks #267 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 26.6%.
Is Aarti Drugs' ROA % too high?
Aarti Drugs' current ROA % of 7.84% is 10% above median its 10-year median of 7.14. Over the past 10 years, this metric has ranged from a low of 6.31 to a high of 16.78. The Drug Manufacturers industry median ROA % is 2.72. Aarti Drugs' value of 7.84% is 188.2% above this industry median. Based on the distribution chart, Aarti Drugs ranks #267 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aarti Drugs has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Drugs' ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aarti Drugs ranks #267 out of 1005 companies for ROA %. This puts Aarti Drugs in the upper half of its industry. The industry median ROA % is 2.72. Aarti Drugs' value of 7.84% is 188.2% above this benchmark. Historically, Aarti Drugs' own ROA % has ranged from 6.31 to 16.78 over the past decade. While the company's 10-year median is 7.14 vs. the industry median of 2.72, Aarti Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarti Drugs's current ROA % of 7.84% is 188.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Aarti Drugs and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Drugs's current ROA % is 7.84%, which is 10% above median its own 10-year median of 7.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Drugs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Drugs (NSE:AARTIDRUGS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹498.02, compared to a current price of ₹386.60 — trading 22.4% below its estimated fair value. The current ROA % is 7.84%, which is 10% above median its 10-year median of 7.14 and 188.2% above the Drug Manufacturers industry median of 2.72. Aarti Drugs' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Aarti Drugs (NSE:AARTIDRUGS), the current ROA % is 7.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued.
The current stock price of ₹386.60 is trading 22.4% below its estimated GF Value™ of ₹498.02.
GuruFocus considers Aarti Drugs to be Modestly Undervalued.
Key valuation signals for NSE:AARTIDRUGS:
ROA %: 7.84% (10% above median its 10-year median of 7.14)
GF Value™: ₹498.02 vs. price of ₹386.60 (22.4% below fair value)
Industry Position: 188.2% above the Drug Manufacturers median (#267 of 1005)
No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
73GF Score
Get the complete analysis for NSE:AARTIDRUGS
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AARTIDRUGS has been successfully added to your 
